Share
6,854 Posts.
lightbulb Created with Sketch. 383
clock Created with Sketch. 18/11/23
18:12
Share
In all honesty I think not. It’s all mind boggling and many agree. One platform deal or one drug deal and it is off to the races.
Originally posted by Eaglenebula:
↑
The thing that strikes me about this is the potential for this to be a disease curing conveyer belt. Find a target organ identify a disease with a single strand mutation and an under expressed protein. Optimise the CPP PMO combination. Run the trials. 62 percent chance of success. I don’t mean to downplay or be flippant about the science I just mean they could already have a large list of targets organised in order of priority. Once revenue is coming in the potential could be enormous. Am I being overly optimistic?
Expand
(20min delay)